WaveMan
WaveMan · Company
ABVX · Abivax S.A.
> Search tickers & screens ⌘K
LIVE
← All companies

ABVX Abivax (ABVX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001956827
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
192
13F, latest reported quarter

Abivax insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Abivax S.A. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
192 funds bought in last quarter
more than 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
12.0% of the float short (float per yahoo 2026-10-26) · 5.0 days to cover · settled 2026-09-30
more than 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ABVX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns ABVX: institutional holders (13F)

13F holdings, latest reported quarter
TCG Crossover Management, LLC
6,007,834 sh
$800.6M
Helikon Investments Ltd
2,787,131 sh
$371.4M
Darwin Global Management, Ltd.
3,621,583 sh
$348.2M
Vestal Point Capital, LP
2,349,443 sh
$313.1M
Jupiter Topco LLC
1,913,933 sh
$255.1M

Congress trades in ABVX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ABVX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ABVX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Dorsey Wright ADR ETF
$1.3M position · as of 2026-06-30
3.1%
Eventide Healthcare & Life Sciences Fund
$52.6M position · as of 2026-06-30
2.9%
Goldman Sachs Hedge Industry VIP ETF
$12.6M position · as of 2026-05-31
2.2%
Harbor Health Care ETF
$891.8K position · as of 2026-07-31
2.2%
ALGER 35 FUND
$848.2K position · as of 2026-07-31
1.8%
ALGER SMALL CAP GROWTH FUND
$3.6M position · as of 2026-07-31
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
19 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
1 active
9
Phase 2
2 active
3
Phase 3
1 active
4
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 192 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ABVX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
no equity line filed
Return on assets
-85.1%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no close on file at or before the as-of date
FCF yield
n/a
no close on file at or before the as-of date
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Net income-$336.1M-$176.2M-$147.7M-$60.7M
SEC XBRL, fiscal years, as known on 2026-10-27

ABVX Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
89
Inputs
  • Funds adding, latest quarter192 · 89 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
33
Inputs
  • Short interest, % of float+12.0% · 33 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: fewer than four consecutive quarters of operating income; no equity line filed
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies